If you liked this article you might like

Opko Health (OPK) Stock Higher After Q2 Earnings Beat
'Mad Money' Lightning Round: I'm Still With Opko Health
Jim Cramer's 'Mad Money' Recap: Four Winning Themes, Four to Avoid
Opko Is a Buying Opportunity After FDA's Approval of Kidney Drug